糖尿病のβ<SUB>1</SUB>-lipoproteinに関する研究
スポンサーリンク
概要
- 論文の詳細を見る
We prepared β<SUB>1</SUB>-lipoprotein from human diabetic serum and studied its diabetogenic action. The Following results were obtained.<BR>1) Intravenously injected insulin I<SUP>131</SUP> was retained in the blood of diabetic patients with and without insulin treatment.<BR>Therefore, it was suggested that diabetics had common unknown extracellular factors in their serum which impeded the distribution of insulin I<SUP>131</SUP> to the tissue. At the same time, the blood sugar reduction by insulin was lower in diabetics than in normals.<BR>2) Diabetic β<SUB>1</SUB>-lipoprotein inhibited the glucose output of rat liver-slices and the glucose uptake of rat diaphragms, but in normal ones it accelerated both.<BR>3) Diabetic β<SUB>1</SUB>-lipoprotein inhibited the binding of insulin I<SUP>131</SUP> to liver, kidney and muscle slices of rats. Consequently it was suggested that the retardative factors of insulin I<SUP>131</SUP> in blood might be diabetic β<SUB>1</SUB>-lipoprotein.<BR>4) Diabetic β<SUB>1</SUB>-lipoprotein intravenously injected, was more distributed than normal to target organs, and the blood concentration of the former was lower than that of the latter. These findings were in contrast with the concentration curve of insulin I<SUP>131</SUP> (mentioned in 1).<BR>At this experiment, after an injection of diabetic β<SUB>1</SUB>-lipoprotein the blood sugar increased but decreased after normal.<BR>5) The greatest amount of injected diabetic β<SUB>1</SUB>-lipoprotein I<SUP>131</SUP> distributed to cell membrane and was not washed out by diffusion.<BR>Therefore, chemical binding of lipoprotein with cell membrane was thought to be the reason.<BR>6) According to the above mentioned findings, it was thought that, Diabetic β<SUB>1</SUB>-lipoprotein intravenously injected, rapidly bound with cell membranes of target organs of insulin and thus inhibited the active transport of glucose of insulin and elevated the blood sugar level.<BR>7) By an intravenous injection of diabetic β<SUB>1</SUB>-lipoprotein blood sugar was slowly increased and reached its maximum after 4 hours of injection and after 6 hours hyperglycemia still continued. By daily injection, continuous hyperglycemia was obtained.<BR>The mechanism of hyperglycemia was thought due to the inhibition of peripheral glucose utilization.<BR>8) An intravenous injection of diabetic β<SUB>1</SUB>-lipoprotein inhibited the action of insulin and elevated the blood sugar level.<BR>9) By the use of infrared-spectrophotometry, it was observed that diabetic β<SUB>1</SUB>-lipoprotein did not contain any unknown substance and the proportion of chemical composition of its fraction was not abnormal.<BR>10) As the result of chemical analysis of diabetic β<SUB>1</SUB>-lipoprotein, cholesterol, phospholipid, neutral fat and protein were slightly larger in quantity than normal.<BR>11) By the use of metachromasy of methylorange it was made clear, that the protein fraction of diabetic β<SUB>1</SUB>-lipoprotein was different from normal.<BR>Therefore the structure of protein of diabetic β<SUB>1</SUB>-lipoprotein seemed to be abnormal.
- 日本内分泌学会の論文
著者
関連論文
- 177) 腎臓に於ける糖代謝に関する研究第1報 腎切片による糖原新成(第24回 日本循環器学会総会)
- 14) 動脈硬化症の成因に関する研究(第3報) : β_1-lipoproteinに就て(第23回日本循環器學會總會)
- 3) Insulin 1^ 代謝により見たる腎の糖代謝に就いて(第5回日本循環器學會近畿地方學會總會)
- 糖尿病のβ1-lipoproteinに関する研究